1. Home
  2. SPRO vs VSTE Comparison

SPRO vs VSTE Comparison

Compare SPRO & VSTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRO
  • VSTE
  • Stock Information
  • Founded
  • SPRO 2013
  • VSTE 2009
  • Country
  • SPRO United States
  • VSTE Australia
  • Employees
  • SPRO N/A
  • VSTE N/A
  • Industry
  • SPRO Biotechnology: Pharmaceutical Preparations
  • VSTE
  • Sector
  • SPRO Health Care
  • VSTE
  • Exchange
  • SPRO Nasdaq
  • VSTE Nasdaq
  • Market Cap
  • SPRO 62.7M
  • VSTE 51.9M
  • IPO Year
  • SPRO 2017
  • VSTE N/A
  • Fundamental
  • Price
  • SPRO $1.17
  • VSTE $1.65
  • Analyst Decision
  • SPRO Buy
  • VSTE
  • Analyst Count
  • SPRO 3
  • VSTE 0
  • Target Price
  • SPRO $5.00
  • VSTE N/A
  • AVG Volume (30 Days)
  • SPRO 470.6K
  • VSTE 8.3M
  • Earning Date
  • SPRO 11-14-2024
  • VSTE 01-01-0001
  • Dividend Yield
  • SPRO N/A
  • VSTE N/A
  • EPS Growth
  • SPRO N/A
  • VSTE N/A
  • EPS
  • SPRO 0.06
  • VSTE N/A
  • Revenue
  • SPRO $106,455,000.00
  • VSTE $342,000.00
  • Revenue This Year
  • SPRO N/A
  • VSTE N/A
  • Revenue Next Year
  • SPRO N/A
  • VSTE N/A
  • P/E Ratio
  • SPRO $17.92
  • VSTE N/A
  • Revenue Growth
  • SPRO 37.01
  • VSTE N/A
  • 52 Week Low
  • SPRO $1.01
  • VSTE $0.83
  • 52 Week High
  • SPRO $1.89
  • VSTE $12.00
  • Technical
  • Relative Strength Index (RSI)
  • SPRO 41.49
  • VSTE 47.45
  • Support Level
  • SPRO $1.28
  • VSTE $1.35
  • Resistance Level
  • SPRO $1.22
  • VSTE $2.45
  • Average True Range (ATR)
  • SPRO 0.07
  • VSTE 0.70
  • MACD
  • SPRO -0.01
  • VSTE -0.16
  • Stochastic Oscillator
  • SPRO 32.73
  • VSTE 5.70

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About VSTE Vast Renewables Limited

Vast Renewables Ltd is a clean, renewable energy company specializing in the design and manufacturing of concentrated solar thermal power (CSP) systems to generate carbon-free, utility-scale electricity, industrial heat, and green fuels. The Company's differentiated modular CSP system, utilizing proprietary sodium loop heat transfer technology, provides customers with a solution to the enduring challenge of intermittent renewable energy through 24/7 dispatchable power and heat.

Share on Social Networks: